| OAE0503 | Catalyzing access to HIV services and essential health care for key populations: effective innovations for African countries | Oral abstract session with live Q&A | Health systems, health systems strengthening and partnerships |
| OAE0504 | Increasing access to SelfCare: Employing a online-based demand generation strategy to increase uptake of peer-led unassisted HIV self-testing among key populations in the Philippines | Oral abstract session with live Q&A | Implementation science and scale up of HIV testing |
| OAE0505 | Differentiated online-to-offline (O2O) interventions for HIV services: impacts on HIV testing and case finding among key populations in Thailand, Nepal and the Philippines | Oral abstract session with live Q&A | Implementation science and scale up of prevention |
| OALBA0502 | CD8 T cell counts negatively correlate with IL-15-mediated HIV reactivation ex vivo | Oral abstract session with live Q&A | Understanding and targeting persistent HIV reservoirs |
| OALBA0503 | Venetoclax, alone and in combination with the BH3-mimetic S63845, depletes HIV-1 latently infected cells and delays rebound in humanized mice | Oral abstract session with live Q&A | Understanding and targeting persistent HIV reservoirs |
| OALBA0504 | Absence of viral rebound for 18 months without antiretrovirals after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells to treat a biphenotypic sarcoma | Oral abstract session with live Q&A | Novel treatment and prevention strategies |
| OALBA0505 | Anti-SIV Env RhmAbs +/- CD8a depletion and N-803 in ART-suppressed rhesus macaques leads to post-treatment control of viremia in a subset of animals | Oral abstract session with live Q&A | Understanding and targeting persistent HIV reservoirs |
| OALBB0502 | A prospective, randomized trial to assess a protease inhibitor–based regimen switch strategy to manage integrase inhibitor–related weight gain | Oral abstract session with live Q&A | Clinical complications of HIV and antiretroviral therapy |
| OALBB0503 | Increasing second-line antiretroviral therapy options for children with HIV in Africa: week-96 efficacy and safety results of the CHAPAS-4 randomised trial | Oral abstract session with live Q&A | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| OALBB0504 | Risks of hypertension with first-line dolutegravir (DTG) and tenofovir alafenamide (TAF) in the NAMSAL and ADVANCE trials | Oral abstract session with live Q&A | Clinical complications of HIV and antiretroviral therapy |